Midwest Leukemia Symposium (Attendee Information)

• Self-screening and Mask Guidance
  • We ask that you self-screen prior to coming on campus. For campus visitors, please use the 1-Check COVID app available to iOS and Android users. For UNMC/Nebraska Medicine employees and students, please use the 1-Check UNMC app.
  • Maintain social distance and wear a mask while on campus. KN95 face masks are still highly recommended but no longer required. Surgical masks are allowed. Cloth masks, gaiters, vented masks, and bandanas are not approved for use. Please bring your own mask.
• Parking
  • Complimentary parking for campus visitors is available in Lot 17 (map). You may enter the parking structure from 45th and Leavenworth (next to La Casa) or from Saddlecreek and Jones Ct. (next to QuikTrip). The stairs from Lot 17 will take you to Emile Street. 
  • Employees and students of UNMC and Nebraska Medicine should park in their regular parking areas.
  • UNMC CCE is not liable for any parking ticket that a participant may incur when attending this symposium.

Read the UNMC CCE Disclosure Declaration Policy

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Zaid S. Al-Kadhimi, MD
  Consultant: Talaris
  Stock Ownership: Moderna, Intalia, Pacific Bio, Regeneron
• Vijaya R. Bhatt, MBBS, MS*
  Consultant: AbbVie, Inc.; Incyte Corporation; Servier Pharmaceuticals LLC
  Drug Support (institutional) for a Trial: Oncoceutics
  Research Funding (institutional): AbbVie, Inc.; Incyte Corporation; Jazz Pharmaceuticals; NMDP; Pfizer, Inc.
  Safety Monitoring Committee: Protagonist
• Krishna Gundabolu, MBBS
  Advisory Board: Bayer Inc.; Blueprints Medicine; Bristol-Myers Squibb; CTI Biopharma; Pfizer, Inc. (Relationships have ended)
• Joseph Khoury, MD
  Scientific Advisor: ANGLE, Plc
• Marlise R. Luskin, MD, MSCE
  Research Funding: AbbVie, Inc.; Novartis
• Geoffrey Uy, MD
  Consultant: Agios; Glaxo Smith Kline; Jazz Pharmaceuticals; Novartis (Relationships have ended)
  Investigational: Flotetuzumab
  Off-label: Venetoclax

 The following have nothing to disclose:

• Prajwal Dhakal, MBBS
• Morgan Mancuso-Sheen, RDN, LMNT
• Hayden D. Sterling, PA-C*
• Meg Trewhitt, APN-BC, AOCNP

 PLANNING COMMITTEE

The following have nothing to disclose:

• Kaitlyn Corley, BSN, RN
• Valeta Creason-Wahl, HMCC
• Christy Johnson, BSN, RN, OCN
• Heidi Keeler, PhD, RN
• Renee Paulin, MSN, RN, CWOCN
• Bailey Wrenn, MA

 *Faculty and planning committee member

The following materials (in PDF) are available for download until Oct. 19, 2022. No part of these materials may be reproduced without prior written permission.

• Low-Grade Myelodysplastic Syndrome (MDS): Diagnostic Difficulties
  Joseph Khoury, MD

• How Do I Treat MDS in 2022?
  Marlise R. Luskin, MD, MSCE

• The Role of Hematopoietic Cell Transplantation in MDS
  Zaid S. Al-Kadhimi, MD

• Supportive Care in Acute Promyelocytic Leukemia
  Prajwal Dhakal, MBBS

• Novel Treatment Options in Acute Lymphocytic Leukemia
  Vijaya R. Bhatt, MBBS, MS

• Management of Relapsed Acute Myeloid Leukemia
  Geoffrey Uy, MD